Alnylam Pharmaceuticals (ALNY) Presents Vutrisiran ATTR-CM Data at ACC.26

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is one of the best future stocks to buy for the next 5 years. On March 30, Alnylam Pharmaceuticals presented new clinical and real-world data at the American College of Cardiology’s Annual Scientific Session/ACC.26 regarding its cardiovascular portfolio. The findings highlight the benefits of vutrisiran, which is an RNAi therapeutic that silences transthyretin/TTR at the source, for patients with transthyretin-mediated amyloidosis with cardiomyopathy/ATTR-CM.

Data from the HELIOS-B analysis showed that vutrisiran improved health-related quality of life and functional outcomes, with treatment effects in older patients appearing comparable to those observed in individuals more than a decade younger. The presentation detailed vutrisiran’s efficacy across the disease spectrum, including those with advanced illness and diastolic dysfunction.

Regarding the hypertension pipeline, Alnylam shared pooled Phase 2 safety data for zilebesiran, an investigational RNAi therapeutic designed to provide continuous blood pressure control through biannual dosing. The results support the ongoing evaluation of zilebesiran in the ZENITH Phase 3 Cardiovascular Outcomes Trial, which was initiated in late 2025 to address cardiovascular risk reduction.

Alnylam Pharmaceuticals (ALNY) Presents Vutrisiran ATTR-CM Data at ACC.26

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is a biotechnology company that develops therapeutics based on ribonucleic acid interference. The company currently has a range of products in Phase 3, Phase 2, and Phase 1 trials.

While we acknowledge the risk and potential of ALNY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ALNY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None.  Follow Insider Monkey on Google News.